Xilio Therapeutics, Inc. is listed today as Xilio Therapeutics, Inc. : market value, financials and filings are on its company page.
Funding rounds 2 counted as startup funding. Open the number of investors for the round's details.
Funding rounds of Xilio Therapeutics, Inc. Month Raised Raise Size Investors Sold Filing Feb 2021 $95 M No. 2 $50 to $250 million 17
Xilio Therapeutics, Inc.: Raise no. 2, Feb 2021 × Investors in this round 17 investors had bought by the notice of Feb 26, 2021: 17 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $95 M of $95 M offered
Smallest investment taken no minimum stated
What was sold equity Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice Joseph Farmer · Executive Officer Rene Russo · Executive Officer, Director Timothy Clackson · Executive Officer Andrew Hack · Director Daniel Curran · Director Daniel Lynch · Director David Gardner · Director David Grayzel · Director Michael Ross · Director Paul Clancy · Director Rachel Humphrey · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Signed by Joseph Farmer, Chief Operating Officer. Newest notice filed Feb 26, 2021. Read the notice at the SEC .
equity SEC Jan 2021 $50 M No. 1 $50 to $250 million 16
Xilio Therapeutics, Inc.: Raise no. 1, Jan 2021 × Investors in this round 16 investors had bought by the notice of Jan 21, 2021: 16 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $50 M of $50 M offered
Smallest investment taken no minimum stated
What was sold equity Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice Joseph Farmer · Executive Officer Rene Russo · Executive Officer, Director Timothy Clackson · Executive Officer Daniel Curran · Director Daniel Lynch · Director David Grayzel · Director Michael Ross · Director Nancy Hong · Director Paul Clancy · Director Peter Dudek · Director Rachel Humphrey · Director Robert Weisskoff · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Signed by Joseph Farmer, Chief Operating Officer. Newest notice filed Jan 21, 2021. Read the notice at the SEC .
equity SEC
What its filings and its own website say, sentence by sentence, each with its source.
Xilio Therapeutics, Inc. chose not to state its revenue in its newest notice of a funding round (Feb 2021).
SEC Form D · Feb 2021
The industry group it chose in its notices: Biotechnology.
SEC Form D · Feb 2021
No products or services of Xilio Therapeutics, Inc. are on record.
No investor of Xilio Therapeutics, Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.
Largest shareholders today Institutions holding Xilio Therapeutics, Inc. shares, as of Sep 30, 2026.
As of Sep 30, 2026
Executives and directors As the company named them in its notices. Directors of a funded startup are often partners of its investors.
People named by Xilio Therapeutics, Inc. Name Role Named in Joseph Farmer Executive officer Feb 2021 Rene Russo Executive officer Feb 2021 Timothy Clackson Executive officer Feb 2021 Andrew Hack Director Feb 2021 Daniel Curran Director Feb 2021 Daniel Lynch Director Feb 2021 David Gardner Director Feb 2021 David Grayzel Director Feb 2021 Michael Ross Director Feb 2021 Paul Clancy Director Feb 2021 Rachel Humphrey Director Feb 2021 Rene Russo Director Feb 2021 Nancy Hong Director Jan 2021 Peter Dudek Director Jan 2021 Robert Weisskoff Director Jan 2021
Went public since 2021. Its SEC number is that of a company listed on a stock exchange.